Stockscreener 앱 받기
9.08
0.55%
0.05
시간 외 거래:
8.87
-0.21
-2.31%
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
MCRB stock declines as Seres Therapeutics pauses SER-155 phase 2 study and shrinks headcount by 30% - MSN
MCRB (NASDAQ: MCRB) files Form 144 to resell 8,553 restricted shares - Stock Titan
Kelly Brady Net Worth (2026) - GuruFocus
Seres Therapeutics schedules 2026 annual meeting for June 9 - Investing.com
Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date - TipRanks
Seres Therapeutics sets 2026 annual meeting for June 9; shareholder proposal deadline Mar 26 - TradingView
Seres Therapeutics (MCRB) schedules 2026 meeting, sets proposal deadline - Stock Titan
Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February - MarketBeat
Layoff Tracker: Inovio Slims Down as Lead Asset Nears Market - BioSpace
MCRB: Canaccord Genuity Maintains Buy Rating with $22 Target | M - GuruFocus
Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
MCRB: Canaccord Genuity Maintains Buy Rating with $22 Target | MCRB Stock News - GuruFocus
MCRB Should I Buy - Intellectia AI
Exit Recap: Is Seres Therapeutics Inc impacted by rising rates2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Seres Therapeutics (NASDAQ:MCRB) Releases Earnings Results, Beats Expectations By $0.50 EPS - MarketBeat
Seres Therapeutics 2025 10-K: $0.8M Revenue, net income $5.70M - TradingView
Seres Therapeutics: Q4 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports 2025 Results, Highlights Refocused Pipeline - TipRanks
Seres (MCRB) Focuses on Advancing Biotherapeutics Portfolio - GuruFocus
Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Seres Therapeutics: Fourth Quarter Earnings Overview - Bitget
Seres Therapeutics (NASDAQ: MCRB) details 2025 profit, cash runway and SER-155 progress - Stock Titan
From $125.8M loss to profit: Seres targets SER-155 for cancer side effects - Stock Titan
Seres Therapeutics (MCRB) awards 56,250 stock options to officer - Stock Titan
Seres Therapeutics (MCRB) officer Brady Kelly reports stock holdings - Stock Titan
Seres Therapeutics Inc expected to post a loss of $2.11 a shareEarnings Preview - TradingView
Is Seres Therapeutics Incs ROE strong enough2025 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Rally Mode: Should I invest in Seres Therapeutics Inc before earningsGold Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Activity Recap: Should I invest in Seres Therapeutics Inc before earningsWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Aug Action: Does Seres Therapeutics Inc have declining or rising EPSMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn
Seres Therapeutics (MCRB) director Richard Kender awarded 150,000 stock options - Stock Titan
Seres Therapeutics (MCRB) grants 75,000-share stock option to officer Henn - Stock Titan
The Escalator: Seres Therapeutics, Bavarian Nordic, Moderna and more - Medical Marketing and Media
Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday - MarketBeat
Human Microbiome Therapeutics Market to Reach US$ 5.86 Billion - openPR.com
MCRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Seres Therapeutics Announces Executive Leadership Changes and Promotions - The Globe and Mail
MCRB: Leadership transition and pipeline progress position the company for key clinical milestones in 2026 - TradingView
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates - The Manila Times
Seres Therapeutics appoints Kender as exec chair, interim CEO - National Today
[8-K] Seres Therapeutics, Inc. Reports Material Event | MCRB SEC FilingForm 8-K - Stock Titan
IPO Launch: Can STEL ride the EV waveQuarterly Trade Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving AverageWhat's Next? - MarketBeat
MCRB Technical Analysis & ETF Price Forecast - Intellectia AI
Setup Watch: Can Seres Therapeutics Inc outperform under higher oil prices2025 Big Picture & Consistent Growth Stock Picks - baoquankhu1.vn
Seres down after pausing investments for lead program - MSN
Seres Therapeutics (MCRB) officer trades RSUs and sells 75 shares - Stock Titan
Market Review: Will Seres Therapeutics Inc benefit from green energy policiesQuarterly Portfolio Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
$3.25+ Bn Human Microbiome Market Trends and Global Forecasts, 2035, Driven by Advancements in Microbiome Sequencing, Rising Investments in R&D, and Increasing Demand for Personalized Medicine - GlobeNewswire Inc.
Will Seres Therapeutics Inc. benefit from green energy policiesJuly 2025 Catalysts & Real-Time Buy Zone Alerts - mfd.ru
Is Seres Therapeutics Inc. stock a good choice for value investorsMarket Trend Review & Real-Time Volume Trigger Notifications - mfd.ru
Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at Wall Street Zen - MarketBeat
MCRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
1.20%
0.06%
자본화:
|
볼륨(24시간):